Is TKPYY.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

118 people get TKPYY.PK articles and Market Currents by email alert.

Get email alerts on TKPYY.PK »

HEADLINES:

Takeda Pharmaceutical Co Ltd. CEO Discusses F4Q2012 Results - Earnings Call Transcript
Thu, May 9
Apricus Biosciences: A Transformative Year Ahead
Chemistfrog • Mon, Apr 1 • 19 Comments
Speculation On The Cause Of The OMONTYS Recall
Chemistfrog • Thu, Feb 28 • 44 Comments
Affymax: Investor Darling In 2012 Now Has To Perform In 2013
Steve Daly • Mon, Jan 21 • 3 Comments
Investing In The Future Of Multiple Myeloma Treatment
Brian L. Wilson • Wed, Jan 16 • 10 Comments
Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma

Business Wire (Dec 9, 2012)
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas

Business Wire (Dec 9, 2012)
Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study

Business Wire (Dec 9, 2012)
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Scott Matusow • Mon, Oct 15, 2012 • 3 Comments
Merck's Blockbuster Drug Januvia And Its Competitors
Peter Geschek • Tue, Aug 28, 2012 • 3 Comments
Dividend Stocks From The Land Of The Rising Sun
Guraaf • Mon, Aug 6, 2012 • 33 Comments
AMAG Receives EU Approval For Iron Drug With Phase III Results Expected Soon
Mike Havrilla • Fri, Jun 22, 2012
Is Furiex Due For A Bounce?
Brian L. Wilson • Tue, Apr 17, 2012
Valeant: Zovirax, New Acquisitions Are Big Money-Spinners
ValueMax • Thu, Apr 12, 2012
9 Healthcare Stocks With Major Catalysts Due in April
Spencer Knight • Mon, Apr 2, 2012 • 8 Comments
Biotechs To Benefit From Strategy Shift By Big Pharma
Brett Korsgaard • Tue, Dec 13, 2011 • 2 Comments
Lower R&D Budgets For Big Pharma Creating A Brighter Future For The Right Biotechs
Brett Korsgaard • Mon, Dec 12, 2011 • 5 Comments
Drug Maker Dividend Stocks With Strong Growth Prospects
Dutch Trader • Wed, Aug 10, 2011 • 11 Comments
Biotech Catalysts for Third Quarter
Chemistfrog • Fri, Jun 24, 2011 • 13 Comments
It May Be Time for Amylin and Lilly to Head to Divorce Court
Stephen Simpson • Fri, May 27, 2011

To learn more about Seeking Alpha Pro, click here.

There are no Focus articles on TKPYY.PK.

Apricus Biosciences: A Transformative Year Ahead
Chemistfrog • Mon, Apr 1 • 19 Comments
Speculation On The Cause Of The OMONTYS Recall
Chemistfrog • Thu, Feb 28 • 44 Comments
Affymax: Investor Darling In 2012 Now Has To Perform In 2013
Steve Daly • Mon, Jan 21 • 3 Comments
Investing In The Future Of Multiple Myeloma Treatment
Brian L. Wilson • Wed, Jan 16 • 10 Comments
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Scott Matusow • Mon, Oct 15, 2012 • 3 Comments
Merck's Blockbuster Drug Januvia And Its Competitors
Peter Geschek • Tue, Aug 28, 2012 • 3 Comments
Dividend Stocks From The Land Of The Rising Sun
Guraaf • Mon, Aug 6, 2012 • 33 Comments
AMAG Receives EU Approval For Iron Drug With Phase III Results Expected Soon
Mike Havrilla • Fri, Jun 22, 2012
Is Furiex Due For A Bounce?
Brian L. Wilson • Tue, Apr 17, 2012
Valeant: Zovirax, New Acquisitions Are Big Money-Spinners
ValueMax • Thu, Apr 12, 2012
9 Healthcare Stocks With Major Catalysts Due in April
Spencer Knight • Mon, Apr 2, 2012 • 8 Comments
Biotechs To Benefit From Strategy Shift By Big Pharma
Brett Korsgaard • Tue, Dec 13, 2011 • 2 Comments
Lower R&D Budgets For Big Pharma Creating A Brighter Future For The Right Biotechs
Brett Korsgaard • Mon, Dec 12, 2011 • 5 Comments
Drug Maker Dividend Stocks With Strong Growth Prospects
Dutch Trader • Wed, Aug 10, 2011 • 11 Comments
Biotech Catalysts for Third Quarter
Chemistfrog • Fri, Jun 24, 2011 • 13 Comments
It May Be Time for Amylin and Lilly to Head to Divorce Court
Stephen Simpson • Fri, May 27, 2011

Takeda Pharmaceutical Co Ltd. CEO Discusses F4Q2012 Results - Earnings Call Transcript
Thu, May 9

Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma

Business Wire (Dec 9, 2012)
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas

Business Wire (Dec 9, 2012)
Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study

Business Wire (Dec 9, 2012)

TKPYY.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for TKPYY.PK.

Sector: Healthcare

Industry: Drug Related Products

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, March 19, 8:18 AM NPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR) Comment! [Healthcare, M&A]
Sunday, February 24, 3:31 AM Affymax (AFFY) and Japan's Takeda Pharmaceutical (TKPHF.PK) have voluntarily recalled all lots of anemia treatment Omontys in the U.S. following reports of "serious hypersensitivity reactions," including fatalities in "0.02%" of over 25,000 patients after an initial injection. The recall comes after Fresenius said earlier this month that it was halting a pilot program using Omontys. (PR) 1 Comment [Healthcare]
Monday, January 7, 12:12 PM Affymax (AFFY +5.4%) and Japanese drug maker Takeda Pharmaceuticals (TKPYY.PK) have entered into a supply agreement for sourcing and supply of Omontys Injection with DSI Renal. Financial terms weren't disclosed, but the agreement allows DSI Renal to purchase the drug for use within its organization, provide discounts and rebates on the product in its selected centers, and then, based on ongoing evaluation, potentially expand to additional facilities. Comment! [Healthcare, On the Move]
Thursday, January 3, 1:03 PM Affymax (AFFY +0.4%) and Takeda Pharmaceuticals (TKPYY.PK) announce that the J-code assigned by the Centers for Medicare and Medicaid Services for Omontys Injection is now effective. This permanent billing code provides streamlined reimbursement for dialysis organizations prescribing the drug for anemia in the United States. Comment! [Healthcare]
Tuesday, September 25, 2012, 4:42 PM Sucampo Pharmaceuticals (SCMP) and Takeda Pharmaceuticals (TKPYY.PK) say the FDA,has granted priority review of their supplemental new drug application for an additional indication for Amitiza, a treatment for opioid-induced constipation in patients with chronic, non-cancer pain. A decision is expected by late January 2013. Shares +7% AH. Comment! [Healthcare, On the Move]
Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
Friday, July 27, 2012, 4:18 PM Furiex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones. Comment! [Healthcare, Global & FX, On the Move]
Monday, July 2, 2012, 2:38 PM Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. Comment! [Healthcare, On the Move, M&A]
Thursday, April 26, 2012, 8:36 AM Furiex Pharmaceuticals (FURX) -27% premarket after the company says the FDA requested further data from partner Takeda Pharmaceutical (TKPYY.PK) regarding the new drug applications for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. Comment! [Healthcare, On the Move]
Wednesday, April 11, 2012, 7:25 AM Takeda Pharmaceutical (TKPYY.PK) buys privately-held URL Pharma for $800M in a deal that could include performance payments down the road. URL's major product is gout treatment Colcrys. Comment! [M&A, Global & FX]
Tuesday, April 10, 2012, 10:39 AM Affymax (AFFY +2.4%) says it received a $50M development-milestone payment from Takeda Pharmaceutical (TKPYY.PK), triggered by the FDA's approval of its Omontys anemia drug late last month. Comment! [On the Move]
Wednesday, March 28, 2012, 3:09 PM Amylin (AMLN +48.6%) investors cheer the rumor it rejected a $3.5B offer from Bristol-Myers Squibb, and analysts expect higher bids. Deutsche Bank says AMLN could be worth up to $31/share given an "acquirer with diabetes sales force can cut SG&A by 80% and R&D by 40%." Piper Jaffray names BMY, MRK and TKPYY.PK as potential sutiors; Leerink Swann suggests AZN. Comment! [Healthcare, M&A, On the Move]
Friday, January 13, 2012, 2:36 PM Seattle Genetics (SGEN -4.8%) and Takeda Pharmaceutical (TKPYY.PK -1.00%) dip after the FDA says it's seen three cases of serious brain infection among patients being treated with their jointly-produced lymphoma drug Adcetris, and strengthened the drug's warning label. Comment! [Healthcare, On the Move]
Thursday, December 15, 2011, 4:57 PM Affymax (AFFY) says Takeda Pharmaceuticals (TKPYY.PK) will not commercialize peginesatide, an investigational therapy for treating patients with anemia due to chronic kidney disease, in Japan. Takeda said commercialization in the area was "not strategically optimal." The companies will continue to collaborate in developing the drug for commericalization outside Japan, including preparing to file for regulatory approvals in the U.S. and Europe. Shares -6.5% AH. Comment! [Healthcare, Global & FX]

TKPYY.PK Takeda Pharma

TKPYY.PK

Takeda Pharma